Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 75

Sort by

Sort Order Select

Journal Articles

Impact of Minimal Residual Disease Analysis in the Era of Rituximab Maintenance in Follicular Lymphoma: Data from “FOLL12” Phase III Trial of the Fondazione Italiana Linfomi

Blood (2024) 144 (Supplement 1): 339.

https://doi.org/10.1182/blood-2024-194832

Published: 2024

Journal Articles

Dissecting Diffuse Large B Cell Lymphoma Heterogeneity: New Insights from a State-Specific Molecular Characterization

Blood (2024) 144 (Supplement 1): 2975.

https://doi.org/10.1182/blood-2024-204797

Published: 2024

Journal Articles

Lenalidomide plus rituximab for the initial treatment of frail older patients with DLBCL: the FIL_ReRi phase 2 study

Blood (2023) 142 (17): 1438–1447.

https://doi.org/10.1182/blood.2022019173

Published: 2023

Includes: Supplemental data

Journal Articles

Serum Level Kinetic of Key Cytokines in Newly Diagnosed Lymphoma Patients during First Line Treatment: Correlation with PET/CT Scan Results and Treatment Outcome

Maria Cosenza, Antonella Franceschetto, Luca Braglia, Chiara Chiavelli, Stefano Panareo, Luigi Marcheselli, Samantha Pozzi, Stefano Sacchi

Blood (2022) 140 (Supplement 1): 11899–11900.

https://doi.org/10.1182/blood-2022-166984

Published: 2022

Journal Articles

Clinico-Pathological, Cytogenetic and Molecular Similarities and Differences between Primary and Secondary Cutaneous Lymphomas

Silvia Uccella, Gaia Goteri, Antonino Maiorana, Valentina Donati, Maria Grazia Tibiletti, Francesca Magnoli, Sofia Facchi, Deborah Merchiori, Erika Morsia, Robel Papotti, Stefania Bettelli, Elisa Forti, Sara Galimberti, Serena Rupoli, Alessandra Filosa, Dimitri Dardanis, Luca Braglia, Samantha Pozzi, Stefano Sacchi

Blood (2022) 140 (Supplement 1): 11887–11888.

https://doi.org/10.1182/blood-2022-166554

Published: 2022

Journal Articles

Preclinical Efficacy and Biological Effects of Venetoclax and Ixazomib in Combination in Lymphoma Cells

Maria Cosenza, MS, Stefano Sacchi, MD, Samantha Pozzi, MD

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-134882

Published: 2020

Journal Articles

COO, MYC / BCL2 Status and R-IPI Define a Group of Poor Prognosis DLBCL Patients in a Real-World Clinical Setting

Stefania Bettelli, Raffaella Marcheselli, Samantha Pozzi, MD, Luigi Marcheselli, Robel Papotti, Elisa Forti, M. Christina Christina Cox, MD PhD, Arianna Di Napoli, Tamar Tadmor, MD, Antonino Maiorana, Valentina Donati, MD, Sara Galimberti, MD PhD, Stefano Sacchi, MD

Blood (2019) 134 (Supplement_1): 1617.

https://doi.org/10.1182/blood-2019-125689

Published: 2019

Journal Articles

Prognostication of Diffuse Large B-Cell Lymphoma By Lympho2Cx Assay and BCL2 and MYC Expression: Application in a Real Life Context of 154 Patients

Stefania Bettelli, Raffaella Marcheselli, Samantha Manfredini, Alessia Bari, MD, Samantha Pozzi, MD, M. Christina Christina Cox, MD PhD, Luigi Marcheselli, Arianna Di Napoli, Ilana Levy, MD, Elisa Forti, Tamar Tadmor, MD, Antonino Maiorana, Stefano Sacchi, MD

Blood (2018) 132 (Supplement 1): 5308.

https://doi.org/10.1182/blood-2018-99-117973

Published: 2018

Journal Articles

Ofatumumab Is Active and Safe in Patients with Relapsed/Refractory Splenic Marginal Zone Lymphoma (SMZL): Results from the Interim Analysis of an Italian Multicenter Phase 2 Study (MORE trial)

Lydia Scarfo, MD, Silvia Ferrari, Annamaria Maria Frustaci, Monica Tani, Samantha Pozzi, MD, Eloise Scarano, Maria Colia, Pamela Ranghetti, Maurilio Ponzoni, MD, Paola Ronchi, MD, Andres JM Ferreri, MD, Paolo Ghia, MD PhD

Blood (2018) 132 (Supplement 1): 4162.

https://doi.org/10.1182/blood-2018-99-113875

Published: 2018

Journal Articles

Combination of Momelotinib and Citarinostat Show Strong Synergistic Effect in Lymphoid Cell Lines Co-Targeting JAK2/STAT3 and HDAC6

Maria Cosenza, MS, Monica Civallero, PhD, Stefano Sacchi, MD, Samantha Pozzi, MD

Blood (2018) 132 (Supplement 1): 3506.

https://doi.org/10.1182/blood-2018-99-116468

Published: 2018

Journal Articles

Absolute Monocyte Count at Diagnosis Could Improve the Prognostic Role of Final FDG-PET in Diffuse Large B Cell Lymphoma Patients

Raffaella Marcheselli, PhD, Antonella Franceschetto, MD, Alessia Bari, MD, Luigi Marcheselli, MS, Tamar Tadmor, MD, Samantha Pozzi, MD, Ilana Levy, MD, Patrizia Pizzichini, MD, Daniela Prosperi, MD, Maria Christina Cox, MD, Rosaria D'Apollo, MD, Lucia Massi, MD, Napoleone Prandini, MD, Stefano Sacchi, MD

Blood (2017) 130 (Supplement 1): 1576.

https://doi.org/10.1182/blood.V130.Suppl_1.1576.1576

Published: 2017

Journal Articles

Ruxolitinib in Combination with Vorinostat Suppresses Tumor Growth and Alters the Metabolic Phenotype in Haematological Diseases

Monica Civallero, PhD, Maria Cosenza, MS, Sandra Marmiroli, MS, Samantha Pozzi, MD, Stefano Sacchi, MD

Blood (2017) 130 (Supplement 1): 5194.

https://doi.org/10.1182/blood.V130.Suppl_1.5194.5194

Published: 2017

Journal Articles

Momelotinib and Citarinostat: Co-Targeting JAK2/STAT3 and HDAC6 in Lymphoid Malignancies, a New Potential Therapeutic Combination

Maria Cosenza, MS, Monica Civallero, PhD, Stefano Sacchi, MD, Samantha Pozzi, MD

Blood (2017) 130 (Supplement 1): 5201.

https://doi.org/10.1182/blood.V130.Suppl_1.5201.5201

Published: 2017

Journal Articles

Co-Targeting Jak Signaling Pathway and Histone Deacetylases Produces Synergistic Activity in Haematologic Malignancies Cell Lines

Monica Civallero, Maria Cosenza, Samantha Pozzi, Stefano Sacchi

Blood (2016) 128 (22): 4717.

https://doi.org/10.1182/blood.V128.22.4717.4717

Published: 2016

Journal Articles

Ricolinostat (ACY-1215), a Selective HDAC6 Inhibitor, Alone and in Combination with Bendamustine Is Effective in Preclinical Studies in Lymphoma Cell Lines

Maria Cosenza, Monica Civallero, Steven N Quayle, Stefano Sacchi, Samantha Pozzi

Blood (2016) 128 (22): 2772.

https://doi.org/10.1182/blood.V128.22.2772.2772

Published: 2016

Journal Articles

The Absolute Monocyte Count at Diagnosis Could Improve the Prognostic Role of the End of Treatment 18-FDG-PET in Diffuse Large B Cell Lymphoma (DLBCL) Patients

Raffaella Marcheselli, Antonella Franceschetto, Luigi Marcheselli, Alessia Bari, Samantha Pozzi, Monica Barbolini, Virginia Rossetti, Rosaria D'Apollo, Napoleone Prandini, Stefano Sacchi

Blood (2016) 128 (22): 5406.

https://doi.org/10.1182/blood.V128.22.5406.5406

Published: 2016

Journal Articles

Neutrophil - Lymphocyte Ratio (NLR) at Diagnosis Is an Independent Prognostic Factor in Patients with Nodular Sclerosis Hodgkin Lymphoma: Results of a Large Multicenter Study Involving 990 Patients

Alessia Bari, Luigi Marcheselli, Tamar Tadmor, Raffaella Marcheselli, Maria Christina Cox, MDPhD, Samantha Pozzi, Angela Ferrari, Luca Baldini, Paolo Gobbi, Massimo Federico, Aaron Polliack, Stefano Sacchi

Blood (2015) 126 (23): 3862.

https://doi.org/10.1182/blood.V126.23.3862.3862

Published: 2015

Journal Articles

Calcium-Carbonate Nanocapsules Improve the Efficacy of BEZ235 in Lymphoma a Cell Line: A Promising New Technology of Drug Delivery

Monica Civallero, Viviana Vergaro, Cinzia Citti, Maria Cosenza, Giuseppe Cannazza, Carlo Parenti, Alessia Bari, Giuseppe Ciccarella, Stefano Sacchi, Samantha Pozzi

Blood (2015) 126 (23): 4851.

https://doi.org/10.1182/blood.V126.23.4851.4851

Published: 2015

Journal Articles

Neutrophil to Lymphocyte Ratio at Diagnosis Is an Independent Prognostic Factor in Diffuse Large B-Cell Lymphoma: Results of a Large Multicenter Study Involving 931 Patients

Luigi Marcheselli, Alessia Bari, Raffaella Marcheselli, Tamar Tadmor, Samantha Pozzi, Maria Christina Cox, MDPhD, Luca Baldini, Angela Ferrari, Paola Ferri, Massimo Federico, Aaron Polliack, Stefano Sacchi

Blood (2015) 126 (23): 1465.

https://doi.org/10.1182/blood.V126.23.1465.1465

Published: 2015

Journal Articles

Prognostic Score Based on Clinical and Biochemical Surrogates of Disease Status in DLBCL Trated with Chemo-Immunotherapy

Luigi Marcheselli, Alessia Bari, MD, Samantha Pozzi, MD, Raffaella Marcheselli, M. Christina Cox, MD, Luca Baldini, Prof, Stefano Luminari, MD, Stefano Sacchi, MD

Blood (2014) 124 (21): 3027.

https://doi.org/10.1182/blood.V124.21.3027.3027

Published: 2014

NARROW

Impact of Minimal Residual Disease Analysis in the Era of Rituximab Maintenance in Follicular Lymphoma: Data from “FOLL12” Phase III Trial of the Fondazione Italiana Linfomi

Dissecting Diffuse Large B Cell Lymphoma Heterogeneity: New Insights from a State-Specific Molecular Characterization

Lenalidomide plus rituximab for the initial treatment of frail older patients with DLBCL: the FIL_ReRi phase 2 study

Serum Level Kinetic of Key Cytokines in Newly Diagnosed Lymphoma Patients during First Line Treatment: Correlation with PET/CT Scan Results and Treatment Outcome

Clinico-Pathological, Cytogenetic and Molecular Similarities and Differences between Primary and Secondary Cutaneous Lymphomas

Preclinical Efficacy and Biological Effects of Venetoclax and Ixazomib in Combination in Lymphoma Cells

COO, MYC / BCL2 Status and R-IPI Define a Group of Poor Prognosis DLBCL Patients in a Real-World Clinical Setting

Prognostication of Diffuse Large B-Cell Lymphoma By Lympho2Cx Assay and BCL2 and MYC Expression: Application in a Real Life Context of 154 Patients

Ofatumumab Is Active and Safe in Patients with Relapsed/Refractory Splenic Marginal Zone Lymphoma (SMZL): Results from the Interim Analysis of an Italian Multicenter Phase 2 Study (MORE trial)

Combination of Momelotinib and Citarinostat Show Strong Synergistic Effect in Lymphoid Cell Lines Co-Targeting JAK2/STAT3 and HDAC6

Absolute Monocyte Count at Diagnosis Could Improve the Prognostic Role of Final FDG-PET in Diffuse Large B Cell Lymphoma Patients

Ruxolitinib in Combination with Vorinostat Suppresses Tumor Growth and Alters the Metabolic Phenotype in Haematological Diseases

Momelotinib and Citarinostat: Co-Targeting JAK2/STAT3 and HDAC6 in Lymphoid Malignancies, a New Potential Therapeutic Combination

Co-Targeting Jak Signaling Pathway and Histone Deacetylases Produces Synergistic Activity in Haematologic Malignancies Cell Lines

Ricolinostat (ACY-1215), a Selective HDAC6 Inhibitor, Alone and in Combination with Bendamustine Is Effective in Preclinical Studies in Lymphoma Cell Lines

The Absolute Monocyte Count at Diagnosis Could Improve the Prognostic Role of the End of Treatment 18-FDG-PET in Diffuse Large B Cell Lymphoma (DLBCL) Patients

Neutrophil - Lymphocyte Ratio (NLR) at Diagnosis Is an Independent Prognostic Factor in Patients with Nodular Sclerosis Hodgkin Lymphoma: Results of a Large Multicenter Study Involving 990 Patients

Calcium-Carbonate Nanocapsules Improve the Efficacy of BEZ235 in Lymphoma a Cell Line: A Promising New Technology of Drug Delivery

Neutrophil to Lymphocyte Ratio at Diagnosis Is an Independent Prognostic Factor in Diffuse Large B-Cell Lymphoma: Results of a Large Multicenter Study Involving 931 Patients

Prognostic Score Based on Clinical and Biochemical Surrogates of Disease Status in DLBCL Trated with Chemo-Immunotherapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only